ARTV
Artiva Biotherapeutics Inc

793
Mkt Cap
$134.95M
Volume
56,048.00
52W High
$7.75
52W Low
$1.47
PE Ratio
-1.59
ARTV Fundamentals
Price
$5.46
Prev Close
$5.23
Open
$5.37
50D MA
$4.96
Beta
1.37
Avg. Volume
142,591.90
EPS (Annual)
-$3.43
P/B
1.22
Rev/Employee
$0.00
$7.80
Loading...
Loading...
News
all
press releases
Artiva Biotherapeutics (ARTV) Expected to Announce Earnings on Monday
Artiva Biotherapeutics (NASDAQ:ARTV) will be releasing its Q4 2025 earnings before the market opens on Monday, March 30. (View Earnings Report at https://www.marketbeat.com/earnings/reports/2026-3-30-artiva-biotherapeutics-inc-stock...
MarketBeat·3d ago
News Placeholder
More News
News Placeholder
Artiva Biotherapeutics, Inc. (NASDAQ:ARTV) Sees Significant Decrease in Short Interest
Artiva Biotherapeutics, Inc. (NASDAQ:ARTV - Get Free Report) was the target of a large decrease in short interest in the month of February. As of February 27th, there was short interest totaling...
MarketBeat·11d ago
News Placeholder
Research Analysts Issue Forecasts for ARTV Q1 Earnings
Artiva Biotherapeutics, Inc. (NASDAQ:ARTV - Free Report) - Investment analysts at HC Wainwright upped their Q1 2026 earnings per share estimates for shares of Artiva Biotherapeutics in a report...
MarketBeat·13d ago
News Placeholder
Artiva Biotherapeutics' (ARTV) Buy Rating Reiterated at Needham & Company LLC
Needham & Company LLC reiterated a "buy" rating and issued a $18.00 price target on shares of Artiva Biotherapeutics in a research note on Wednesday...
MarketBeat·15d ago
News Placeholder
Artiva Biotherapeutics Pivots to Rheumatoid Arthritis at TD Cowen, Teases 2026 RA Data Update
Artiva Biotherapeutics (NASDAQ:ARTV) used a presentation and fireside chat at TD Cowen's 46th Annual Healthcare Conference to outline its strategy in deep B-cell depletion for autoimmune disease...
MarketBeat·21d ago
News Placeholder
Artiva Biotherapeutics, Inc. (NASDAQ:ARTV) Given Average Recommendation of "Moderate Buy" by Analysts
Artiva Biotherapeutics, Inc. (NASDAQ:ARTV - Get Free Report) has received an average recommendation of "Moderate Buy" from the six brokerages that are covering the stock, MarketBeat.com reports. One...
MarketBeat·24d ago
News Placeholder
Artiva Biotherapeutics, Inc. (NASDAQ:ARTV) Short Interest Down 28.5% in January
Artiva Biotherapeutics, Inc. (NASDAQ:ARTV - Get Free Report) was the recipient of a large decrease in short interest in January. As of January 30th, there was short interest totaling 203,792 shares...
MarketBeat·1mo ago
News Placeholder
Artiva Biotherapeutics, Inc. (NASDAQ:ARTV) Receives Consensus Rating of "Moderate Buy" from Brokerages
Artiva Biotherapeutics, Inc. (NASDAQ:ARTV - Get Free Report) has been given a consensus rating of "Moderate Buy" by the six analysts that are presently covering the stock, Marketbeat.com reports. One...
MarketBeat·2mo ago
News Placeholder
Artiva Biotherapeutics, Inc. (NASDAQ:ARTV) Sees Significant Decline in Short Interest
Artiva Biotherapeutics, Inc. (NASDAQ:ARTV - Get Free Report) saw a large drop in short interest in January. As of January 15th, there was short interest totaling 284,944 shares, a drop of 27.1% from...
MarketBeat·2mo ago
News Placeholder
Brokers Set Expectations for ARTV FY2030 Earnings
Artiva Biotherapeutics, Inc. (NASDAQ:ARTV - Free Report) - Analysts at HC Wainwright issued their FY2030 earnings per share estimates for shares of Artiva Biotherapeutics in a research report issued...
MarketBeat·2mo ago
<
1
2
...
>

Latest ARTV News

View
Top Discussions

Advertisement|Remove ads.

Advertisement|Remove ads.